Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Par Pharmaceutical, a manufacturer of generic drugs and niche pharmaceuticals, has gained rights to Teva Pharmaceuticals' three products.
Subscribe to our email newsletter
As per the agreement, Par will own the abbreviated new drug application (ANDA) of fentanyl citrate lozenges, a generic version of Actiq.
It will also own ANDA of cyclobenzaprine ER capsules, the generic version of Amrix, as well as the US rights to market modafinil tablets, the generic version of Provigil.
Par is currently shipping all strengths of fentanyl citrate lozenges to the trade that were previously available from Teva.
Cyclobenzaprine ER capsules and modafinil tablets were not previously marketed by Teva and are not yet available.